David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.
Inside the Clinic
David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.
Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.
Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.
Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.
Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.
EP. 7: Inside the Clinic: JTCC Experts Share Strategies for When CAR T-Cell Therapy Is Not an Option
Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.
Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.
Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.
Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.
Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5